ENDRA Life Sciences Inc.
NDRA
$3.45
-$0.21-5.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 62.67% | -184.28% | 24.08% | 12.82% | 5.68% |
| Total Depreciation and Amortization | -18.13% | -24.18% | -23.30% | -31.09% | -21.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -169.40% | 474.56% | 245.79% | -81.05% | 97.64% |
| Change in Net Operating Assets | -78.35% | 117.74% | -229.07% | 218.00% | -16.38% |
| Cash from Operations | 39.70% | 30.30% | 36.23% | 8.17% | 14.46% |
| Capital Expenditure | 35.93% | 100.00% | -- | -- | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 27.31% | -100.00% | -- | -- | 11.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -70.69% | -100.00% | -- | 55.71% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | -68.91% | -100.00% | -99.85% | 55.05% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.46% | -202.78% | -11.49% | 113.70% | 32.94% |